Despite increased global interest in testosterone deficiency in men and its treatment with testosterone therapy, practical aspects of care remain confusing to many practitioners. Testosterone deficiency can result from testicular dysfunction (primary hypogonadism) or hypothalamic–pituitary dysfunction (secondary hypogonadism), and be congenital or acquired. Sexual and nonsexual symptoms of testosterone deficiency can negatively affect quality of life and cause considerable general health concerns. Investigation of testosterone deficiency should be undertaken in men with symptoms of reduced libido, erectile dysfunction, depression, fatigue, poor concentration, and poor memory. Total and free testosterone are the most frequently used tests and evaluating serum concentrations of luteinizing hormone aids determination of primary versus secondary testosterone deficiency. Multiple formulations of testosterone therapy are available, but symptomatic benefits might not manifest for several weeks to many months; long-acting formulations are convenient and improve compliance. Concerns regarding cardiovascular and prostate cancer risks are not supported by current evidence, monitoring during therapy is mandatory. On balance, testosterone therapy can be considered a safe and effective treatment for testosterone deficiency.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Testosterone Deficiency, Weakness, and Multimorbidity in Men
Scientific Reports Open Access 12 April 2018
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Handelsman, D. J. Global trends in testosterone prescribing, 2000–2011: expanding the spectrum of prescription drug misuse. Med. J. Aust. 199, 548–551 (2013).
Allan, C. A. & McLachlan, R. I. Androgens and obesity. Curr. Opin. Endocrinol. Diabetes Obes. 17, 224–232 (2010).
Saad, F., Aversa, A., Isidori, A. M. & Gooren, L. J. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr. Diabetes Rev. 8, 131–143 (2012).
Saad, F. & Gooren, L. J. The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. J. Obes. http://dx.doi.org/10.1155/2011/471584 (2011).
Yassin, A. & Doros, G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clin. Obes. 3, 73–83 (2013).
Traish, A. M., Guay, A., Feeley, R. & Saad, F. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J. Androl. 30, 10–22 (2009).
Traish, A. M., Haider, A., Doros, G. & Saad, F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int. J. Clin. Pract. 68, 14–29 (2014).
Jones, T. H. et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 34, 828–837 (2011).
Traish, A. M., Saad, F. & Guay, A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J. Androl. 30, 23–32 (2009).
Morris, P. D. & Channer, K. S. Testosterone and cardiovascular disease in men. Asian J. Androl. 14, 428–435 (2012).
Traish, A. M., Saad, F., Feeley, R. J. & Guay, A. The dark side of testosterone deficiency: III. Cardiovascular disease. J. Androl. 30, 477–494 (2009).
Saad, F. Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease? Diabetes Metab. Res. Rev. 28 (Suppl. 2), 52–59 (2012).
Yeap, B. B. Androgens and cardiovascular disease. Curr. Opin. Endocrinol. Diabetes Obes. 17, 269–276 (2010).
Fink, H. A. et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J. Clin. Endocrinol. Metab. 91, 3908–3915 (2006).
Drummond, E. S., Harvey, A. R. & Martins, R. N. Androgens and Alzheimer's disease. Curr. Opin. Endocrinol. Diabetes Obes. 16, 254–259 (2009).
Khera, M. Patients with testosterone deficit syndrome and depression. Arch. Esp. Urol. 66, 729–736 (2013).
Hyde, Z. et al. Low free testosterone predicts frailty in older men: the health in men study. J. Clin. Endocrinol. Metab. 95, 3165–3172 (2010).
Yeap, B. B. et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. J. Clin. Endocrinol. Metab. 99, E9–E18 (2014).
Laughlin, G. A., Barrett-Connor, E. & Bergstrom, J. Low serum testosterone and mortality in older men. J. Clin. Endocrinol. Metab. 93, 68–75 (2008).
Araujo, A. B. et al. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 96, 3007–3019 (2011).
Menke, A. et al. Sex steroid hormone concentrations and risk of death in US men. Am. J. Epidemiol. 171, 583–592 (2010).
Malkin, C. J. et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 96, 1821–1825 (2010).
Camacho, E. M. et al. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur. J. Endocrinol. 168, 445–455 (2013).
Travison, T. G., Araujo, A. B., Kupelian, V., O'Donnell, A. B. & McKinlay, J. B. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J. Clin. Endocrinol. Metab. 92, 549–555 (2007).
Wu, F. C. et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J. Clin. Endocrinol. Metab. 93, 2737–2745 (2008).
Bhasin, S. et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 95, 2536–2559 (2010).
Buvat, J., Maggi, M., Guay, A. & Torres, L. O. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J. Sex Med. 10, 245–284 (2013).
Corona, G., Rastrelli, G., Vignozzi, L., Mannucci, E. & Maggi, M. How to recognize late-onset hypogonadism in men with sexual dysfunction. Asian J. Androl. 14, 251–259 (2012).
Hall, S. A. et al. Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. J. Clin. Endocrinol. Metab. 93, 3870–3877 (2008).
Saad, F., Yassin, A., Doros, G., Haider, A. Effects of long-term treatment with testosterone on weight and waist size in 411 hypognadal men with obesity class I-III:observational data from two registry studies. Int. J. Obes. (Lond.) http://dx.doi.org/10.1038/ijo.2015.139.
Corona, G. et al. Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. Int. J. Impot. Res. 18, 190–197 (2006).
Dhindsa, S. et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J. Clin. Endocrinol. Metab. 89, 5462–5468 (2004).
Grossmann, M. et al. Low testosterone and anaemia in men with type 2 diabetes. Clin. Endocrinol. (Oxf.) 70, 547–553 (2009).
Grossmann, M. et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J. Clin. Endocrinol. Metab. 93, 1834–1840 (2008).
Mulligan, T., Frick, M. F., Zuraw, Q. C., Stemhagen, A. & McWhirter, C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int. J. Clin. Pract. 60, 762–769 (2006).
Pellitero, S. et al. Hypogonadotropic hypogonadism in morbidly obese males is reversed after bariatric surgery. Obes. Surg. 22, 1835–1842 (2012).
Schooling, C. M., Au Yeung, S. L., Freeman, G. & Cowling, B. J. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med. 11, 57 (2013).
Corona, G. et al. The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction. J. Sex. Med. 7, 1547–1556 (2010).
Cohen, P. G. Statins and male hypogonadism. J. Sex. Med. 8, 1826 (2011).
Reid, I. R., Wattie, D. J., Evans, M. C. & Stapleton, J. P. Testosterone therapy in glucocorticoid-treated men. Arch. Intern. Med. 156, 1173–1177 (1996).
Crawford, B. A., Liu, P. Y., Kean, M. T., Bleasel, J. F. & Handelsman, D. J. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J. Clin. Endocrinol. Metab. 88, 3167–3176 (2003).
Brennan, M. J. The effect of opioid therapy on endocrine function. Am. J. Med. 126, S12–S18 (2013).
Aloisi, A. M. et al. Endocrine consequences of opioid therapy. Psychoneuroendocrinology 34 (Suppl. 1), S162–168 (2009).
Daniell, H. W. Hypogonadism in men consuming sustained-action oral opioids. J. Pain 3, 377–384 (2002).
Wu, F. C. et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N. Engl. J. Med. 363, 123–135 (2010).
Rhoden, E. L. & Morgentaler, A. Risks of testosterone-replacement therapy and recommendations for monitoring. N. Engl. J. Med. 350, 482–492 (2004).
Saad, F. et al. Effects of testosterone on erectile function: implications for the therapy of erectile dysfunction. BJU Int. 99, 988–992 (2007).
Bhasin, S. et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 91, 1995–2010 (2006).
Wang, C. et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J. Androl. 30, 1–9 (2009).
Dohle, G. R. et al., European Association of Urology guidelines on male hypogonadism, 2014. uroweb.org [online]
Morgentaler, A., Khera, M., Maggi, M. & Zitzmann, M. Commentary: who is a candidate for testosterone therapy? A synthesis of international expert opinions. J. Sex. Med. 11, 1636–1645 (2014).
Scovell, J. M., Ramasamy, R., Wilken, N., Kovac, J. R. & Lipshultz, L. I. Hypogonadal symptoms in young men are associated with a serum total testosterone threshold of 400 ng/dL. BJU Int. 116, 142–146 (2015).
Shea, J. L., Wongt, P. Y. & Chen, Y. Free testosterone: clinical utility and important analytical aspects of measurement. Adv. Clin. Chem. 63, 59–84 (2014).
Lepage, R. Measurement of testosterone and its sub-fractions in Canada. Clin. Biochem. 39, 97–108 (2006).
Vermeulen, A., Verdonck, L. & Kaufman, J. M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab. 84, 3666–3672 (1999).
Gray, A., Feldman, H. A., McKinlay, J. B. & Longcope, C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J. Clin. Endocrinol. Metab. 73, 1016–1025 (1991).
Paduch, D. A. et al. The laboratory diagnosis of testosterone deficiency. Urology 83, 980–988 (2014).
Reyes-Vallejo, L., Lazarou, S. & Morgentaler, A. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone. J. Sex. Med. 4, 1757–1762 (2007).
Cohen, P. G. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt--a major factor in the genesis of morbid obesity. Med. Hypotheses 52, 49–51 (1999).
Fui, M. N., Dupuis, P. & Grossmann, M. Lowered testosterone in male obesity: mechanisms, morbidity and management. Asian J. Androl. 16, 223–231 (2014).
Winters, S. J., Kelley, D. E. & Goodpaster, B. The analog free testosterone assay: are the results in men clinically useful? Clin. Chem. 44, 2178–2182 (1998).
Fritz, K. S., McKean, A. J., Nelson, J. C. & Wilcox, R. B. Analog-based free testosterone test results linked to total testosterone concentrations, not free testosterone concentrations. Clin. Chem. 54, 512–516 (2008).
Kacker, R., Hornstein, A. & Morgentaler, A. Free testosterone by direct and calculated measurement versus equilibrium dialysis in a clinical population. Aging Male 16, 164–168 (2013).
Moreno, S. A., Shyam, A. & Morgentaler, A. Comparison of free testosterone results by analog radioimmunoassay and calculated free testosterone in an ambulatory clinical population. J. Sex. Med. 7, 1948–1953 (2010).
Gupta, S. K., Lindemulder, E. A. & Sathyan, G. Modeling of circadian testosterone in healthy men and hypogonadal men. J. Clin. Pharmacol. 40, 731–738 (2000).
Winters, S. J. Diurnal rhythm of testosterone and luteinizing hormone in hypogonadal men. J. Androl. 12, 185–190 (1991).
Morgentaler, A. Commentary: Guideline for male testosterone therapy: a clinician's perspective. J. Clin. Endocrinol. Metab. 92, 416–417 (2007).
Bremner, W. J., Vitiello, M. V. & Prinz, P. N. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J. Clin. Endocrinol. Metab. 56, 1278–1281 (1983).
Brambilla, D. J., Matsumoto, A. M., Araujo, A. B. & McKinlay, J. B. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J. Clin. Endocrinol. Metab. 94, 907–913 (2009).
Plymate, S. R., Tenover, J. S. & Bremner, W. J. Circadian variation in testosterone, sex hormone-binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men. J. Androl. 10, 366–371 (1989).
Luboshitzky, R., Shen-Orr, Z. & Herer, P. Middle-aged men secrete less testosterone at night than young healthy men. J. Clin. Endocrinol. Metab. 88, 3160–3166 (2003).
Collier, C. P. et al. The significance of biological variation in the diagnosis of testosterone deficiency, and consideration of the relevance of total, free and bioavailable testosterone determinations. J. Urol. 183, 2294–2299 (2010).
Tajar, A. et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J. Clin. Endocrinol. Metab. 95, 1810–1818 (2010).
Rhoden, E. L., Estrada, C., Levine, L. & Morgentaler, A. The value of pituitary magnetic resonance imaging in men with hypogonadism. J. Urol. 170, 795–798 (2003).
Finkelstein, J. S. et al. Gonadal steroids and body composition, strength, and sexual function in men. N. Engl. J. Med. 369, 1011–1022 (2013).
Behre, H. M. & Nieschlag, E. in Testosterone—Action, Deficiency, Substitution 4th edn (eds Nieschlag, E. & Behre, H. M.) 309–335 (2012).
Giagulli, V. A. et al. Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: focus on new formulations. Curr. Pharm. Des. 17, 1500–1511 (2011).
Schulte-Beerbuhl, M. & Nieschlag, E. Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate of testosterone cypionate. Fertil. Steril. 33, 201–203 (1980).
Minnemann, T. et al. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism. J. Endocrinol. Invest. 31, 718–723 (2008).
Corona, G., Maseroli, E. & Maggi, M. Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin. Pharmacother. 15, 1903–1926 (2014).
Schubert, M. et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J. Clin. Endocrinol. Metab. 89, 5429–5434 (2004).
Jockenhovel, F. et al. Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men. Eur. J. Endocrinol. 160, 815–819 (2009).
Jockenhovel, F., Vogel, E., Reinhardt, W. & Reinwein, D. Effects of various modes of androgen substitution therapy on erythropoiesis. Eur. J. Med. Res. 2, 293–298 (1997).
Fabbri, A., Giannetta, E., Lenzi, A. & Isidori, A. M. Testosterone treatment to mimic hormone physiology in androgen replacement therapy. A view on testosterone gel and other preparations available. Expert Opin. Biol. Ther. 7, 1093–1106 (2007).
Abadilla, K. A. & Dobs, A. S. Topical testosterone supplementation for the treatment of male hypogonadism. Drugs 72, 1591–1603 (2012).
de Ronde, W. Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies. Hum. Reprod. 24, 425–428 (2009).
Stahlman, J. et al. Serum testosterone levels in non-dosed females after secondary exposure to 1.62% testosterone gel: effects of clothing barrier on testosterone absorption. Curr. Med. Res. Opin. 28, 291–301 (2012).
Roth, M. Y. & Amory, J. K. Pharmacologic development of male hormonal contraceptive agents. Clin. Pharmacol. Ther. 89, 133–136 (2011).
Coviello, A. D. et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J. Clin. Endocrinol. Metab. 90, 2595–2602 (2005).
Saad, F. et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur. J. Endocrinol. 165, 675–685 (2011).
Morgentaler, A. et al. Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months. J. Sex. Med. 11, 2818–2825 (2014).
Khera, M. et al. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J. Urol. 186, 1005–1011 (2011).
Morgentaler, A. & Rhoden, E. L. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology 68, 1263–1267 (2006).
Calof, O. M. et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J. Gerontol. A Biol. Sci. Med. Sci. 60, 1451–1457 (2005).
Coviello, A. D. et al. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J. Clin. Endocrinol. Metab. 93, 914–919 (2008).
Lazarou, S., Reyes-Vallejo, L. & Morgentaler, A. Wide variability in laboratory reference values for serum testosterone. J. Sex Med. 3, 1085–1089 (2006).
Francomano, D., Greco, E. A., Lenzi, A. & Aversa, A. CAG repeat testing of androgen receptor polymorphism: is this necessary for the best clinical management of hypogonadism? J. Sex. Med. 10, 2373–2381 (2013).
Zitzmann, M. The role of the CAG repeat androgen receptor polymorphism in andrology. Front. Horm. Res. 37, 52–61 (2009).
Lunenfeld, B. et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male 18, 5–15 (2015).
Lakshman, K. M. et al. The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. J. Clin. Endocrinol. Metab. 95, 3955–3964 (2010).
Kacker, R., Traish, A. M. & Morgentaler, A. Estrogens in men: clinical implications for sexual function and the treatment of testosterone deficiency. J. Sex. Med. 9, 1681–1696 (2012).
Amory, J. K. et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J. Clin. Endocrinol. Metab. 89, 503–510 (2004).
Tan, R. S., Cook, K. R. & Reilly, W. G. High estrogen in men after injectable testosterone therapy: the low T experience. Am. J. Mens Health 9, 229–234 (2015).
Vanderschueren, D. et al. Gonadal sex steroid status and bone health in middle-aged and elderly European men. Osteoporos. Int. 21, 1331–1339 (2010).
Vanderschueren, D. et al. Sex steroid actions in male bone. Endocr. Rev. 35, 906–960 (2014).
Ohlsson, C., Borjesson, A. E. & Vandenput, L. Sex steroids and bone health in men. Bonekey Rep. 1, 2 (2012).
Clarke, B. L. & Khosla, S. Androgens and bone. Steroids 74, 296–305 (2009).
Burnett-Bowie, S. A., McKay, E. A., Lee, H. & Leder, B. Z. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J. Clin. Endocrinol. Metab. 94, 4785–4792 (2009).
Meriggiola, M. C. et al. Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals. J. Sex. Med. 5, 2442–2453 (2008).
Yeap, B. B. Sex steroids and cardiovascular disease. Asian J. Androl. 16, 239–247 (2014).
Vandenplas, G. et al. Endogenous oestradiol and cardiovascular disease in healthy men: a systematic review and meta-analysis of prospective studies. Heart 98, 1478–1482 (2012).
Rhoden, E. L. & Morgentaler, A. Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole. Int. J. Impot. Res. 16, 95–97 (2004).
Morgentaler, A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur. Urol. 50, 935–939 (2006).
Roddam, A. W. et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J. Natl Cancer Inst. 100, 170–183 (2008).
Cui, Y., Zong, H., Yan, H. & Zhang, Y. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 17, 132–143 (2014).
Wang, C. et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur. Urol. 55, 121–130 (2009).
Pastuszak, A. W. et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J. Urol. 190, 639–644 (2013).
Aversa, A., Francomano, D. & Lenzi, A. Cardiometabolic complications after androgen deprivation therapy in a man with prostate cancer: effects of 3 years intermittent testosterone supplementation. Front. Endocrinol. (Lausanne) 3, 17 (2012).
Morgentaler, A. et al. Testosterone therapy in men with untreated prostate cancer. J. Urol. 185, 1256–1260 (2011).
Finkle, W. D. et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE 9, http://dx.doi.org/10.1371/journal.pone.0085805 (2014).
Vigen, R. et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 310, 1829–1836 (2013).
Morgentaler, A. et al. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin. Proc. 90, 224–251 (2015).
Morgentaler, A. Testosterone, cardiovascular risk, and hormonophobia. J. Sex. Med. 11, 1362–1366 (2014).
Morgentaler, A. Will I have a heart attack or stroke if I take testosterone therapy? J. Sex. Med. 11, 1601–1602 (2014).
Morgentaler, A. & Kacker, R. Andrology: Testosterone and cardiovascular risk—deciphering the statistics. Nat. Rev. Urol. 11, 131–132 (2014).
Morgentaler, A. & Lunenfeld, B. Testosterone and cardiovascular risk: world's experts take unprecedented action to correct misinformation. Aging Male 17, 63–65 (2014).
Page, S. T. Testosterone, cardiovascular disease, and mortality in men: living in the dark. Lancet Diabetes Endocrinol. 2, 609–611 (2014).
Corona, G. et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin. Drug Saf. 13, 1327–1351 (2014).
Basaria, S. et al. Adverse events associated with testosterone administration. N. Engl. J. Med. 363, 109–122 (2010).
Xu, L., Freeman, G., Cowling, B. J. & Schooling, C. M. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 11, 108 (2013).
Haring, R. et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20–79. Eur. Heart J. 31, 1494–501 (2010).
Hyde, Z. et al. Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study. J. Clin. Endocrinol. Metab. 97, 179–189 (2012).
Khaw, K. T. et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 116, 2694–2701 (2007).
Muraleedharan, V., Marsh, H., Kapoor, D., Channer, K. S. & Jones, T. H. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur. J. Endocrinol. 169, 725–733 (2013).
Shores, M. M., Matsumoto, A. M., Sloan, K. L. & Kivlahan, D. R. Low serum testosterone and mortality in male veterans. Arch. Intern. Med. 166, 1660–1665 (2006).
Shores, M. M., Smith, N. L., Forsberg, C. W., Anawalt, B. D. & Matsumoto, A. M. Testosterone treatment and mortality in men with low testosterone levels. J. Clin. Endocrinol. Metab. 97, 2050–2058 (2012).
Francomano, D., Bruzziches, R., Barbaro, G., Lenzi, A. & Aversa, A. Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study. J. Endocrinol. Invest. 37, 401–411 (2014).
Aversa, A. et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J. Sex. Med. 7, 3495–3503 (2010).
Basaria, S. et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA. 11, 570–581 (2015).
English, K. M., Steeds, R. P., Jones, T. H., Diver, M. J. & Channer, K. S. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 102, 1906–1911 (2000).
Webb, C. M., Adamson, D. L., de Zeigler, D. & Collins, P. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am. J. Cardiol. 83, 437–439, (1999).
Rosano, G. M. et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 99, 1666–1670 (1999).
Caminiti, G. et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J. Am. Coll. Cardiol. 54, 919–927 (2009).
Malkin, C. J. et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur. Heart J. 27, 57–64 (2006).
Pugh, P. J., Jones, R. D., West, J. N., Jones, T. H. & Channer, K. S. Testosterone treatment for men with chronic heart failure. Heart 90, 446–447 (2004).
Francomano, D. et al. Acute endothelial response to testosterone gel administration in men with severe hypogonadism and its relationship to androgen receptor polymorphism: a pilot study. J. Endocrinol. Invest. http://dx.doi.org/10.1007/s40618-015-0325-4.
A.A. has received speaker's honoraria from Bayer, Eli-Lilly and Menarini. A.M. has been on the scientific advisory board or worked as a consultant for AbbVie Inc., Auxilium Pharmaceuticals, Inc., Clarus Therapeutics, Endo Pharmaceuticals, and TesoRx, has received research funding from Antares Pharma, Auxilium Pharmaceuticals, Inc., Lipocine Inc. and Eli Lilly and has received lecture honoraria from Bayer and Pfizer, he also owns stock as a cofounder of MHB Labs, LLC
Rights and permissions
About this article
Cite this article
Aversa, A., Morgentaler, A. The practical management of testosterone deficiency in men. Nat Rev Urol 12, 641–650 (2015). https://doi.org/10.1038/nrurol.2015.238
This article is cited by
Iter diagnostico e terapeutico dell’ipogonadismo maschile nelle diverse fasi della vita
Testosterone Deficiency, Weakness, and Multimorbidity in Men
Scientific Reports (2018)
Testosterone in renal transplant patients: effect on body composition and clinical parameters
Journal of Nephrology (2018)
Testosterone reference ranges and diagnosis of testosterone deficiency
Nature Reviews Urology (2017)
La sessualità nell’anziano